Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD

1.35  -0.01 (-0.74%)

After market: 1.35 0 (0%)

Fundamental Rating

3

Taking everything into account, CERS scores 3 out of 10 in our fundamental rating. CERS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. CERS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CERS has reported negative net income.
In the past year CERS had a positive cash flow from operations.
In the past 5 years CERS always reported negative net income.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.41%, CERS is in the better half of the industry, outperforming 60.73% of the companies in the same industry.
The Return On Equity of CERS (-37.26%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.41%
ROE -37.26%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CERS's Gross Margin of 59.89% is in line compared to the rest of the industry. CERS outperforms 59.16% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
CERS has more shares outstanding than it did 5 years ago.
CERS has a worse debt/assets ratio than last year.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -5.08, we must say that CERS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.08, CERS is doing worse than 66.49% of the companies in the same industry.
The Debt to FCF ratio of CERS is 9.88, which is on the high side as it means it would take CERS, 9.88 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.88, CERS is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
CERS has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
CERS's Debt to Equity ratio of 1.16 is on the low side compared to the rest of the industry. CERS is outperformed by 76.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF 9.88
Altman-Z -5.08
ROIC/WACCN/A
WACC9.97%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CERS has a Current Ratio of 2.39. This indicates that CERS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.39, CERS perfoms like the industry average, outperforming 45.55% of the companies in the same industry.
A Quick Ratio of 1.79 indicates that CERS should not have too much problems paying its short term obligations.
CERS has a Quick ratio (1.79) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 1.79
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.11% over the past year.
The Revenue has been growing slightly by 7.77% in the past year.
CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)7.77%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%8.64%

3.2 Future

CERS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.86% yearly.
Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 12.84% on average per year.
EPS Next Y14.69%
EPS Next 2Y36.75%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue Next Year24.85%
Revenue Next 2Y17.47%
Revenue Next 3Y12.84%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CERS is valued cheaper than 80.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 29.43
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CERS's earnings are expected to grow with 19.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.75%
EPS Next 3Y19.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (4/25/2025, 8:00:00 PM)

After market: 1.35 0 (0%)

1.35

-0.01 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners76.25%
Inst Owner Change0.01%
Ins Owners4.57%
Ins Owner Change19.1%
Market Cap250.82M
Analysts81.82
Price Target4.34 (221.48%)
Short Float %5.66%
Short Ratio6.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.32%
Min EPS beat(2)15.99%
Max EPS beat(2)34.64%
EPS beat(4)3
Avg EPS beat(4)18.02%
Min EPS beat(4)-5.03%
Max EPS beat(4)34.64%
EPS beat(8)5
Avg EPS beat(8)19.06%
EPS beat(12)8
Avg EPS beat(12)12.33%
EPS beat(16)11
Avg EPS beat(16)13.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.94%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-3.91%
Min Revenue beat(4)-8.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-7.14%
Revenue beat(12)5
Avg Revenue beat(12)-2.07%
Revenue beat(16)9
Avg Revenue beat(16)1.09%
PT rev (1m)8.97%
PT rev (3m)8.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.23%
EPS NY rev (1m)-17.45%
EPS NY rev (3m)-22.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.39%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)7.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.25
P/FCF 29.43
P/OCF 22.08
P/B 4.47
P/tB 4.57
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.05
FCFY3.4%
OCF(TTM)0.06
OCFY4.53%
SpS1.08
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.41%
ROE -37.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.89%
FCFM 4.23%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF 9.88
Debt/EBITDA N/A
Cap/Depr 152.94%
Cap/Sales 1.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 1.79
Altman-Z -5.08
F-Score5
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y14.69%
EPS Next 2Y36.75%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue 1Y (TTM)7.77%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%8.64%
Revenue Next Year24.85%
Revenue Next 2Y17.47%
Revenue Next 3Y12.84%
Revenue Next 5YN/A
EBIT growth 1Y45.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year187.64%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y117.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.31%
OCF growth 3YN/A
OCF growth 5YN/A